Physician profile
Christopher Song
NPI 1003192667
$5,556.29
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $153 · 2022: $5,309 · 2023: $51.75 · 2024: $42.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $94.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $94.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ischemaview, INC. | $5,250.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $130.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $81.26 | 2021-2022 | |
| Heartflow, INC. | $69.81 | 2023-2024 | Ffrct |
| Siemens Medical Solutions USA, INC. | $24.27 | 2023 | Syngo.Via |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.